Annual report pursuant to Section 13 and 15(d)

Debt - Additional Information (Details)

Debt - Additional Information (Details)							1 Months Ended		12 Months Ended				47 Months Ended
Debt - Additional Information (Details)	Oct. 28, 2024	Sep. 08, 2020 USD ($) Debtinstrument $ / shares shares	Apr. 30, 2020 USD ($)	Jan. 21, 2020 USD ($) Debtinstrument $ / shares shares	Apr. 27, 2018 USD ($) $ / shares shares	Nov. 18, 2015 USD ($)	Dec. 31, 2020 USD ($)	Nov. 30, 2020 USD ($)	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2024 USD ($) $ / shares shares	Mar. 01, 2022	Apr. 17, 2018 shares
Debt Instrument [Line Items]
Accretion of debt discounts and deferred financing costs									$ 2,288,000	$ 2,339,000	$ 2,338,000
Aggregate principal amount of exchangeable notes													$ 40,691,000
Issuance of ordinary shares on conversion of exchangeable notes (in shares) \| shares													3,760,155
Pfizer License Agreement
Debt Instrument [Line Items]
Regulatory milestone payments upon approval of product						$ 20,000,000
Regulatory and sales milestone deferred payment period	2 years
Regulatory and sales milestone deferred payment annual rate						8.00%
Ordinary Shares
Debt Instrument [Line Items]
Issuance of ordinary shares on conversion of exchangeable notes (in shares) \| shares										167,599
Loan and Security Agreement \| Silicon Valley Bank (SVB)
Debt Instrument [Line Items]
Loan and security agreement entered date									Apr. 27, 2018
Funded amount under agreement					$ 15,000,000
Remaining borrowing facility available date					Oct. 31, 2019
Maximum amount available under agreement					$ 30,000,000
Frequency of amortization payments									monthly
Date of first required payment of initial draw					Nov. 01, 2019
Minimum fixed interest rate per annum					8.31%
Final interest rate payment on outstanding principal					4.20%
Final payment fee					$ 630,000
Principal payment during the period											1,552,000
Effective annual interest rate on outstanding debt														12.51%
Interest expense											16,000
Accretion of debt discounts and deferred financing costs											6,000
Loan and Security Agreement \| Silicon Valley Bank (SVB) \| Wall Street Journal Prime Rate
Debt Instrument [Line Items]
Basis spread on interest rate					3.89%
Loan and Security Agreement \| Silicon Valley Bank (SVB) \| Maximum
Debt Instrument [Line Items]
Maximum amount available under second draw					$ 15,000,000
Silicon Valley Bank and Life Sciences Fund II LLC \| Ordinary Shares
Debt Instrument [Line Items]
Number of warrants to purchase ordinary shares \| shares					1,326				1,326				1,326
Silicon Valley Bank and Life Sciences Fund II LLC \| Series B Convertible Preferred Shares
Debt Instrument [Line Items]
Number of warrants to purchase ordinary shares \| shares					19,890										19,890
Warrants to purchase preferred shares, exercise price \| $ / shares					$ 282.75				$ 282.75				$ 282.75
2025 Exchangeable Notes
Debt Instrument [Line Items]
Interest expense									$ 723,000	$ 811,000	820,000
Accretion of debt discounts and deferred financing costs									2,288,000	2,339,000	2,344,000
Aggregate principal amount				$ 9,891,000					11,117,000				$ 11,117,000
Debt instrument, outstanding principal									$ 11,117,000	$ 11,117,000			$ 11,117,000
Fair value of derivative liability				27,038,000
Fair value of derivative liability related to rights offering		$ 82,000
Financing transaction costs												$ 2,848,000
Financing transaction costs, capitalized							$ 2,814,000					$ 2,814,000
2025 Exchangeable Notes \| Private Placement
Debt Instrument [Line Items]
Aggregate principal amount				51,588,000
Debt instrument price per unit				$ 1,000
2025 Exchangeable Notes \| Private Placement and Rights Offering
Debt Instrument [Line Items]
Aggregate principal amount		51,800,000
Debt instrument interest rate				6.50%
2025 Exchangeable Notes \| Rights Offering
Debt Instrument [Line Items]
Aggregate principal amount		220,000
Debt instrument price per unit		1,000
RLNs \| Private Placement
Debt Instrument [Line Items]
Aggregate principal amount				$ 103,000
Number of debt instruments within each notes \| Debtinstrument				50
RLNs \| Private Placement and Rights Offering
Debt Instrument [Line Items]
Aggregate principal amount		500		$ 100,000
RLNs \| Rights Offering
Debt Instrument [Line Items]
Aggregate principal amount		$ 440
Number of debt instruments within each notes \| Debtinstrument		50
Securities \| Private Placement
Debt Instrument [Line Items]
Debt instrument price per unit				$ 1,000
Debt instrument, shares embedded within each unit, shares \| shares				66.666					191.7028
Debt instrument, shares embedded within each unit, value				$ 1,000					$ 1,000
Debt instrument, shares embedded within each unit, exchange price \| $ / shares				$ 15					$ 5.2164
Securities \| Rights Offering
Debt Instrument [Line Items]
Debt instrument price per unit		$ 1,000
Debt instrument, shares embedded within each unit, shares \| shares		66.666
Debt instrument, shares embedded within each unit, value		$ 1,000
Debt instrument, shares embedded within each unit, exchange price \| $ / shares		$ 15
Paycheck Protection Program \| Silicon Valley Bank (SVB) \| Iterum Therapeutics US Limited
Debt Instrument [Line Items]
Interest expense											0
Aggregate principal amount			$ 744,000
Debt instrument interest rate			1.00%
Debt instrument maturity period			2 years
Debt instrument, description									Under the terms of the agreement, there were no payments due by the Company until the SBA remitted the forgiveness amount to Iterum US Limited or until after the 10 months after the end of the six-month period beginning April 30, 2020 (the Deferral Period). Following the Deferral Period, equal monthly repayments of principal and interest were due to fully amortize the principal amount outstanding on the PPP loan by the maturity date.
Debt instrument, forgiveness loan								$ 340,000
Debt instrument, remaining amount amortized							$ 404,000
Debt Instrument, principal repayments											$ 69,000